These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20827233)

  • 21. Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?
    Lima A; Bernardes M; Azevedo R; Medeiros R; Seabra V
    Int J Mol Sci; 2015 Jun; 16(6):13760-80. PubMed ID: 26086825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook.
    Selvestrel D; Lucafò M; Pugnetti L; Pagarin S; Moressa V; Pastore S; Taddio A; Stocco G; Decorti G
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1131-1142. PubMed ID: 34392756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
    Chen Y; Zou K; Sun J; Yang Y; Liu G
    Pharmacogenomics; 2018 Apr; 19(6):529-538. PubMed ID: 29589488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.
    Ćalasan MB; Wulffraat NM
    Expert Rev Clin Immunol; 2014 Jul; 10(7):843-54. PubMed ID: 24857620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations.
    Becker ML; van Haandel L; Gaedigk R; Lasky A; Hoeltzel M; Stobaugh J; Leeder JS
    Arthritis Rheum; 2010 Jun; 62(6):1803-12. PubMed ID: 20191581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic characterization of remission in juvenile idiopathic arthritis.
    Jiang K; Frank M; Chen Y; Osban J; Jarvis JN
    Arthritis Res Ther; 2013 Aug; 15(4):R100. PubMed ID: 24000795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
    Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
    Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.
    Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V
    Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.
    Bulatovic M; Heijstek MW; Van Dijkhuizen EH; Wulffraat NM; Pluijm SM; de Jonge R
    Ann Rheum Dis; 2012 Sep; 71(9):1484-9. PubMed ID: 22473625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
    Ferrara G; Mastrangelo G; Barone P; La Torre F; Martino S; Pappagallo G; Ravelli A; Taddio A; Zulian F; Cimaz R;
    Pediatr Rheumatol Online J; 2018 Jul; 16(1):46. PubMed ID: 29996864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Methotrexate in the therapy of juvenile idiopathic arthritis].
    Holzinger D; Frosch M; Föll D
    Z Rheumatol; 2010 Aug; 69(6):496-504. PubMed ID: 20632181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
    J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
    Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
    Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response.
    Becker ML; Gaedigk R; van Haandel L; Thomas B; Lasky A; Hoeltzel M; Dai H; Stobaugh J; Leeder JS
    Arthritis Rheum; 2011 Jan; 63(1):276-85. PubMed ID: 20954192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
    Kostik MM; Gaidar EV; Hynnes AY; Dubko MF; Masalova VV; Snegireva LS; Chikova IA; Isupova EA; Nikitina TN; Serogodskaya ED; Kalashnikova OV; Ravelli A; Chasnyk VG
    Clin Exp Rheumatol; 2016; 34(4):714-8. PubMed ID: 27385618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.
    Bulatović Ćalasan M; Vastert SJ; Scholman RC; Verweij F; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
    Rheumatology (Oxford); 2015 Sep; 54(9):1724-34. PubMed ID: 25877908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Serum MRP8/14 in Predicting Response to Methotrexate in Children With Juvenile Idiopathic Arthritis.
    Bagri NK; Karmakar S; Haldar P; Lodha R; Kabra SK
    J Clin Rheumatol; 2021 Dec; 27(8):e336-e341. PubMed ID: 32658390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.